Durysta™ (bimatoprost implant, for intracameral administration)

Durysta (bimatoprost intracameral implant) is covered for reducing IOP in open‑angle glaucoma or ocular hypertension only for adults (≥18) who have not had prior Durysta in the treated eye and who have documented inadequate efficacy or severe adverse events to at least two ophthalmic prostaglandins and to at least two products from two different pharmacologic classes, with the implant administered by or under the supervision of an ophthalmologist. Approval is limited to one implant per treated eye (one dose) with a maximum of two implants per patient; re‑treatment of previously Durysta‑treated eyes is excluded.

"Durysta (bimatoprost implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension."

Sign up to see full coverage criteria, indications, and limitations.